MedTrace Logo

Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)

NCT04930549 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-02-06

No results posted yet for this study

Summary

This study aims to determine whether dapaglfiflozin 12-week administration is associated with a beneficial impact on the vasculature of patients with chronic kidney disease.

Conditions

  • Renal Insufficiency, Chronic

Interventions

DRUG

Dapagliflozin 10Mg Tab

Patients receive dapagliflozin 10mg tablets once a day during 12 weeks

DRUG

Placebo

Patients receive placebo tablets once a day during 12 weeks

PROCEDURE

impedance cardiography

impedance cardiography (PhysioFlow® PF-05 Lab1TM, Manatec Biomedical) is done for evaluation of cardiac function

PROCEDURE

Applanation tonometry

Applanation tonometry will be done using SphygmoCor®, Hogimed) is done for evaluation of arterial stiffness

PROCEDURE

post-ischemic hyperemia of forearm

An arterial occlusion cuff will be placed on the forearm, and will be deflated to allow post-ischemic hyperemia with the continuous measurements of brachial artery diameter and blood flow velocity by high-resolution echotracking coupled to a Doppler system (ArtLab system®)

PROCEDURE

haemodynamics parameters

haemodynamics parameters will be evaluated using automatic oscillometric recorder

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • University Hospital, Rouen

    lead OTHER

Principal Investigators

  • Dominique Guerrot, MD, PhD · University Hospital, Rouen

  • Jeremy Bellien, PharmD, PhD · University Hospital, Rouen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-18
Primary Completion
2024-09-23
Completion
2024-09-23

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04930549 on ClinicalTrials.gov